Treatment of melanoma brain metastases

Current Opinion in Oncology

Volumn 28, Issue 2, 2016, Pages 159-165

  Goldinger, Simone M ^a   Panje, Cédric ^b   Nathan, Paul ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

immunotherapy; melanoma brain metastases; radiotherapy; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; NIVOLUMAB; PDCD1 PROTEIN, HUMAN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE; TRAMETINIB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; HUMAN; INTERMETHOD COMPARISON; LOCAL THERAPY; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; IMMUNOTHERAPY; MELANOMA; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; QUALITY OF LIFE; SECONDARY; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; INDOLES; MELANOMA; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; QUALITY OF LIFE; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84957431837     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000270     Document Type: Review

References (66)

1. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007; 12:884-898.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5-29.
3. Meier S, Baumert BG, Maier T, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 2004; 27:145-149.
4. Johnson DB, Menzies AM, Zimmer L, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer 2015; 51:2792-2799
5. Ray S, Dacosta-Byfield S, Ganguli A, et al. Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer. J Neurooncol 2013; 114:117-125.
6. Atkins MB, Sosman JA, Agarwala S, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: A phase II Cytokine Working Group study. Cancer 2008; 113:2139-2145.
7. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004; 22:2101-2107.
8. Chang J, Atkinson H, A'Hern R, et al. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer 1994; 30A:2093-2095.
9. Vecchio S, Spagnolo F, Merlo DF, et al. The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival. Melanoma Res 2014; 24:61-67.
10. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293-1300.
11. de la Fuente M, Beal K, Carvajal R, Kaley TJ. Whole-brain radiotherapy in patients with brain metastases from melanoma. CNS Oncol 2014; 3:401-406.
12. Sahgal A, Larson D, Knisely J. Stereotactic radiosurgery alone for brain metastases. Lancet Oncol 2015; 16:249-250.
13. Kocher M, Wittig A, PirothMD, et al. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 2014; 190:521-532.
14. Chowdhury IH, Ojerholm E, McMillan MT, et al. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases. Radiat Oncol 2015; 10:248.
15. Wilkins A, Furness A, Corbett RW, et al. The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma. Br J Cancer 2015; 113:1275-1281.
16. Hong AM, Suo C, Valenzuela M, et al. Low incidence of melanoma brain metastasis in the hippocampus. Radiother Oncol 2014; 111:59-62.
17. Frakes JM, Figura ND, Ahmed KA, et al. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. J Neurosurg 2015. [Epub ahead of print]
18. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
19. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigatorchoice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16:908-918.
20. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-330.
21. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-384.
22. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015.
23. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889-1894.
24. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13:459-465.
25. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-2017.
26. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:1270-1271.
27. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521-2532.
28. Long GVea. Low-dose ipilimumab/pembrolizumab reduces toxicity in advanced melanoma. Presented at SMR Congress 2015. San Francisco 2015.
29. Kluger HM, Goldberg SB, Sznol M, et al. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. J Clin Oncol 2015; 33 (Suppl; abstr 9009).
30. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34.
31. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015; 161:1681-1696.
32. Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 2015; 47:996-1002.
33. Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50:611-621.
34. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012; 379:1893-1901.
35. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095.
36. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358-362.
37. Thumar J, Shahbazian D, Aziz SA, et al. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer 2014; 13:45.
38. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A nonrandomised, open-label phase 2 study. Lancet Oncol 2013; 14:249-256.
39. Rebecca VW, Alicea GM, Paraiso KH, et al. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res 2014; 27:1154-1158.
40. Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol 2015; 38:119-125.
41. Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol 2015; 25:28-33.
42. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate nonredundant immune mechanisms in cancer. Nature 2015; 520:373-377.
43. Patel KR, Shoukat S, Oliver DE, et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 2015. [Epub ahead of print]
44. Mathew M, Tam M, Ott PA, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 2013; 23:191-195.
45. Knisely JP, Yu JB, Flanigan J, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117:227-233.
46. Silk AW, Bassetti MF, West BT, et al. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2:899-906.
47. Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015; 92:368-375.
48. Tazi K, Hathaway A, Chiuzan C, Shirai K. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 2015; 4:1-6.
49. Patel KR, Lawson DH, Kudchadkar RR, et al. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol 2015; 17:1312-1321.
50. Hecht M, Zimmer L, Loquai C, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 2015; 26:1238-1244.
51. Peuvrel L, Ruellan AL, Thillays F, et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 2013; 23:879-881.
52. Conen K, Mosna-Firlejczyk K, Rochlitz C, et al. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. Dermatology 2015; 230:1-4.
53. Ahmed KA, Freilich JM, Sloot S, et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 2015; 122:121-126.
54. Gaudy-Marqueste C, Carron R, Delsanti C, et al. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 2014; 25:2086-2091.
55. Narayana A, Mathew M, Tam M, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113:411-416.
56. Ly D, Bagshaw HP, Anker CJ, et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg 2015; 123: 395-401.
57. Davies MA, Liu P,McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117:1687-1696.
58. Bucheit AD, ChenG, Siroy A, et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res 2014; 20:5527-5536.
59. McArthur G, Larkin J, Dréno B, et al. 25LBA: Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) +vemurafenib (VEM) in the phase 3 coBRIM study. Eur J Cancer 2015; 51:. Supplement S3(September).
60. Davies MA, Stemke-Hale K, Lin E, et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 2009; 15:7538-7546.
61. Cho JH, Robinson JP, Arave RA, et al. AKT1 activation promotes development of melanoma metastases. Cell Rep 2015; 13:898-905
62. Sundstrom T, Espedal H, Harter PN, et al. Melanoma brain metastasis is independent of lactate dehydrogenase A expression. Neuro Oncol 2015; 17:1374-1385.
63. Niessner H, Forschner A, Klumpp B, et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med 2013; 2:76-85.
64. Richtig E, Asslaber M, Partl R, et al. Lack of P-glycoprotein expression in melanoma brain metastases of different melanoma types. Clin Neuropathol 2015. [Epub ahead of print]
65. Vaidhyanathan S, Wilken-Resman B, Ma DJ, et al. Factors influencing the CNS distribution of a novel PI3K/mTOR inhibitor GSK2126458: implications for overcoming resistance with combination therapy for melanoma brain metastases. J Pharmacol Exp Ther 2015. [Epub ahead of print]
66. Chen G, Chakravarti N, Aardalen K, et al. Molecular profiling of patientmatched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res 2014; 20:5537-5546.